Literature DB >> 8039647

Second trial of mesalamine therapy in the treatment of active Crohn's disease.

J Singleton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039647     DOI: 10.1016/0016-5085(94)90210-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  7 in total

1.  Nonobstructing Crohn's Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-04

2.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Inflammatory bowel disease in the elderly. Practical treatment guidelines.

Authors:  G A Akerkar; M A Peppercorn
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

5.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

6.  Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease.

Authors:  Barrett G Levesque; Sunanda V Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

Review 7.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.